Clinical, Genetic, and Cellular Consequences of Mutations in the NA,K-ATPase ATP1A3
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Dystonia
- Sponsor
- State University of New York at Buffalo
- Enrollment
- 198
- Locations
- 2
- Primary Endpoint
- RDP Severity
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purposes of this study are to identify persons with rapid-onset dystonia-parkinsonism (RDP) or mutations of the RDP gene, document prevalence of the disease, and map its natural history.
Detailed Description
Rapid-onset dystonia-parkinsonism (RDP) is a rare, movement disorder with variable characteristics ranging from sudden onset (hours to days) of severe dystonic spasms to gradual onset of writer's cramp. RDP has elements of both dystonia and Parkinson's disease-two neurological diseases with motor and neuropsychological symptoms that hinder the quality of life. An internal trigger associated with extreme physiological stress has been reported prior to abrupt symptom onset of RDP. This study, which is a continuation of an earlier study begun by Dr. Allison Brashear, aims to more clearly identify the characteristics associated with RDP and to explore whether mutations in the RDP gene are associated with atypical dystonias, Parkinson's disease, and other movement disorders. The study involves in-person or remote (telemedicine) neurological assessments and blood samples for genetic analysis.
Investigators
Allison Brashear, MD, MBA
Dean, Jacobs School of Medicine and Biomedical Sciences
State University of New York at Buffalo
Eligibility Criteria
Inclusion Criteria
- •clinical presentation consistent with ATP1A3 disease (RDP, AHC) or confirmed diagnosis of RDP or AHC
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
RDP Severity
Time Frame: Visit 1 (baseline)
History of symptom onset and duration will be obtained and current degree of severity assessed.
Secondary Outcomes
- Presence of neuropsychiatric disease(Will be assessed at Visits 1 (baseline) and 2 (24 months), approximately 2 years apart)